FrancophonIA/ELRC3.0 huggingface dataset:
English: See section 4.4 Reported in ≥ 2 % of subjects and ≥ 1 % more and at least 3 more subjects treated with dapagliflozin 10 mg compared to placebo.
Croatian: Vidjeti dio 4.4 Prijavljeno u ≥ 2% ispitanika liječenih dapagliflozinom u dozi od 10 mg i ≥ 1% te u najmanje 3 ispitanika više nego kod primjene placeba.
English: • diabetic ketoacidosis, seen rarely (may affect up to 1 in 1,000 people) These are the signs of diabetic ketoacidosis (see also section 2 Warnings and precautions): - increased levels of “ketone bodies” in your urine or blood - rapid weight loss - feeling sick or being sick - stomach pain - excessive thirst - fast and deep breathing - confusion - unusual sleepiness or tiredness - a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat.
Croatian: - povišene razine „ketonskih tijela“ u mokraći ili krvi - nagli gubitak tjelesne težine - mučnina ili povraćanje - bol u trbuhu - prekomjerna žeđ - ubrzano i duboko disanje - smetenost - neuobičajena pospanost ili umor - zadah slatkog mirisa, slatki ili metalni okus u ustima ili drugačiji miris mokraće ili znoja.
English: Mean changes from baseline in haematocrit were 2.30 % for dapagliflozin 10 mg versus -0.33 % for placebo.
Croatian: Srednje vrijednosti promjene od početne vrijednosti hematokrita iznosile su 2,30% kod primjene dapagliflozina u dozi od 10 mg i -0,33% kod primjene placeba.
English: Urinary tract infections were more frequently reported for dapagliflozin compared to placebo in a pooled analysis up to 24 weeks (see section 4.8).
Croatian: U analizi objedinjenih podataka za razdoblje do 24 tjedna, infekcije mokraćnih putova češće su prijavljene kod primjene dapagliflozina nego kod primjene placeba (vidjeti dio 4.8).
English: Skin and subcutaneous tissue disorders
Croatian: Poremećaji bubrega i mokraćnog sustava dizurija poliurija
English: At Weeks 24 and 104, minor episodes of hypoglycaemia were reported, respectively, in 40.3 % and 53.1 % of subjects who received dapagliflozin 10 mg plus insulin and in 34.0 % and 41.6 % of the subjects who received placebo plus insulin.
Croatian: Blage epizode hipoglikemije prijavljene su u 40,3% (tjedan 24) odnosno 53,1% (tjedan 104) ispitanika koji su primali dapagliflozin u dozi od 10 mg i inzulin te u 34,0% (tjedan 24) odnosno 41,6% (tjedan 104) ispitanika koji su uz inzulin primali placebo.
English: • redness of the skin (erythema),itching or an itchy rash (hives)
Croatian: • crvenilo kože (eritem), svrbež ili osip koji svrbi (koprivnjača)
English: Adverse reactions in dapagliflozin and metformin immediate-release clinical trial and postmarketing data
Croatian: Nuspojave iz kliničkog ispitivanja dapagliflozina i metformina s trenutnim otpuštanjem te iz podataka prikupljenih nakon stavljanja lijeka u promet Organski sustav
English: In subjects ≥ 65 years of age, a higher proportion of subjects treated with dapagliflozin had adverse reactions related to volume depletion (see section 4.8).
Croatian: Među bolesnicima u dobi od ≥ 65 godina nuspojave povezane s deplecijom volumena javile su se u većem udjelu u ispitanika liječenih dapagliflozinom (vidjeti dio 4.8).
English: In a 52-week, active-controlled non-inferiority study (with 52- and 104-week extension periods), dapagliflozin 10 mg was evaluated as add-on therapy to metformin compared with a sulphonylurea
Croatian: U 52-tjednom ispitivanju neinferiornosti kontroliranom aktivnim lijekom (s produžecima od 52, odnosno 104 tjedna) ocjenjivao se dapagliflozin u dozi od 10 mg kao dodatak metforminu u usporedbi sa sulfonilurejom (glipizidom) kao dodatkom metforminu u bolesnika u kojih glikemija nije bila dovoljno dobro regulirana (HbA1c > 6,5% i ≤ 10%).
English: Talc (E553b) Titanium dioxide (E171) Iron oxide yellow (E172) Iron oxide red (E172)
Croatian: Film ovojnica: poli(vinilni alkohol) (E1203) makrogol 3350 (E1520(iii)) talk (E553b) titanijev dioksid (E171) željezov oksid, žuti (E172) željezov oksid, crveni (E172)
English: EU/1/13/900/007 Xigduo 5 mg/1000 mg 14 tablets EU/1/13/900/008 Xigduo 5 mg/1000 mg 28 tablets
Croatian: EU/1/13/900/004 Xigduo 5 mg/850 mg 60 tableta
English: a) in an active-controlled study comparing dapagliflozin with glipizide as add-on to metformin
Croatian: Rezultati ispitivanja kontroliranog aktivnim lijekom u kojem su se uspoređivali dapagliflozin i glipizid kao dodaci metforminu nakon 52 tjedna (LOCF
English: In subjects ≥ 65 years of age, a higher proportion of subjects treated with dapagliflozin had adverse reactions related to renal impairment or failure compared with placebo.
Croatian: Među bolesnicima u dobi od ≥ 65 godina nuspojave povezane s oštećenjem bubrežne funkcije ili zatajenjem bubrega imao je veći broj ispitanika liječenih dapagliflozinom nego oni koji su primali placebo.
English: Haematocrit increased Creatinine renal clearance decreased Dyslipidaemia
Croatian: Pretrage povišene vrijednosti hematokrita smanjeni klirens bubrežnog kreatinina dislipidemija povišene vrijednosti kreatinina u krvi
English: a) in a placebo-controlled study of dapagliflozin in combination with insulin (alone or with oral glucose-lowering medicinal products, including metformin)
Croatian: Tablica 5. Rezultati placebom kontroliranog ispitivanja dapagliflozina u kombinaciji s inzulinom (samim ili s peroralnim lijekovima za snižavanje razine glukoze, uključujući metformin) nakon 24 tjedna (LOCF
English: Dapagliflozin as an add-on to metformin alone or metformin plus sitagliptin, sulphonylurea or insulin (with or without additional oral glucose-lowering medicinal products, including metformin) resulted in statistically significant body weight reduction up to 24 weeks (p < 0.0001, Tables 3, 4 and 5).
Croatian: Dapagliflozin kao dodatak liječenju metforminu samom ili u kombinaciji sa sitagliptinom, sulfonilurejom ili inzulinom (s ili bez dodatnih lijekova za snižavanje razine glukoze, uključujući metformin) doveo je do statistički značajnog smanjenja tjelesne težine u 24. tjednu.
English: a) placebo-controlled studies up to 24 weeks of dapagliflozin in add-on combination with metformin or metformin plus sitagliptin Add-on combination
Croatian: Tablica 3. Rezultati placebom kontroliranih ispitivanja dapagliflozina kao dodatka u kombiniranom liječenju metforminom ili metforminom i sitagliptinom u trajanju od 24 tjedna (LOCF
English: The efficacy of dapagliflozin, a component of this medicinal product, is dependent on renal function, and efficacy is reduced in patients who have moderate renal impairment and likely absent in patients with severe renal impairment.Therefore, this medicinal product is not recommended for use in patients with moderate to severe renal impairment (patients with GFR < 60 mL/min) (see section 4.2).
Croatian: Djelotvornost dapagliflozina, sastavnice ovog lijeka, ovisi o bubrežnoj funkciji, pa je tako njegova djelotvornost smanjena u bolesnika s umjerenim oštećenjem bubrežne funkcije, dok će u bolesnika s teškim oštećenjem bubrežne funkcije vjerojatno u potpunosti izostati.
English: What Xigduo contains • The active substances are dapagliflozin and metformin hydrochloride (metformin HCl).
Croatian: • Djelatne tvari su dapagliflozin i metforminklorid.
English: At Weeks 24, HbA1c change from baseline in subjects treated with dapagliflozin plus insulin with metformin was -0.93 %.
Croatian: U ispitanika liječenih dapagliflozinom u kombinaciji s inzulinom i metforminom promjena vrijednosti HbA1c u tjednu 24 je u odnosu na početnu vrijednost iznosila -0,93%.
English: For patients inadequately controlled on metformin monotherapy or metformin in combination with other glucose-lowering medicinal products including insulin The recommended dose is one tablet twice daily.
Croatian: Za bolesnike u kojih glikemija nije dovoljno dobro regulirana monoterapijom metforminom ili metforminom u kombinaciji s drugim lijekovima za snižavanje razine glukoze, uključujući inzulin
English: Haematocrit increase was observed with dapagliflozin treatment (see section 4.8); therefore, caution in patients with already elevated haematocrit is warranted.
Croatian: Kod liječenja dapagliflozinom opaženo je povišenje vrijednosti hematokrita (vidjeti dio 4.8).
English: Randomised and treated patients with baseline and at least 1 post-baseline efficacy measurement.
Croatian: LOCF: Prijenos zadnjih zabilježenih vrijednosti (Last observation carried forward) Randomizirani i liječeni ispitanici kod kojih je mjerena djelotvornost pri početnoj vrijednosti i barem jednom nakon početne vrijednosti
English: Suspension (inactivated):
Croatian: Suspenzija (inaktivirana):
English: ATC vet code: QI07AI02.
Croatian: ATCvet kod: QI07AI02.
English: If protection against Rabies is required:
Croatian: Ako je potrebna zaštita od bjesnoće:
English: Active immunisation of dogs from 6 weeks of age:
Croatian: Aktivna imunizacija pasa starijih od 6 tjedana:
English: Date of last renewal: 08/04/2019.
Croatian: Datum posljednjeg produljenja odobrenja: 08/04/2019.
English: EXP {month/year} Once reconstituted, use immediately.
Croatian: ROK VALJANOSTI EXP {mjesec/godina} Jednom rekonstituiran, odmah upotrijebiti.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 07/05/2014.
Croatian: Datum prvog odobrenja: 07/05/2014.
English: However, in field studies 10% of sero-negative dogs did not show seroconversion (>0.1 IU/ml) 3-4 weeks after single primary vaccination against rabies.
Croatian: Međutim, u terenskom ispitivanju 10% seronegativnih pasa nije pokazalo serokonverziju (> 0,1 IU/ml) 3-4 tjedna nakon prvog osnovnog cijepljenja protiv bjesnoće.
English: ** Antibody micro agglutination-lytic reaction.
Croatian: ** mikro aglutinacijska-litička reakcija antitijela.
English: In situations where very high maternally derived antibody levels are expected, the vaccination protocol should be planned accordingly.
Croatian: U slučajevima kada se očekuje posebno visoka razina majčinskih protutijela protokol cijepljenja treba biti posebno planiran.
English: * Tissue culture infectious dose 50%.
Croatian: * 50% infektivne doze tkivne kulture.
English: VIAL (1 ML SUSPENSION)
Croatian: BOČICA (1 ML SUSPENZIJE)
English: Immunocompetence of the animal may be compromised by a variety of factors including poor health, nutritional status, genetic factors, concurrent drug therapy and stress.
Croatian: Imunokompetencija životinje može biti ugrožena zbog raznih čimbenika uključujući loše zdravstveno stanje, gojno stanje, genetske čimbenike usporednu terapiju drugim lijekovima i stres.
English: Adjuvant: Aluminium hydroxide
Croatian: Adjuvans: Aluminijev hidroksid
English: However, due to the low pathogenicity of these strains, it is not necessary to keep vaccinated dogs separated from nonvaccinated dogs and domestic cats.
Croatian: Budući da je mala patogenost tih sojeva, nije potrebno odvojeno držati cijepljene od necijepljenih pasa i domaćih mačaka.
English: Protective immune response against CAV-2 associated respiratory disease is considered to last at least 3 years.
Croatian: Zaštitni imuni odgovor protiv CAV-2 povezan s dišnom bolesti smatra se da traje najmanje 3 godine.
English: Pharmacotherapeutic group: Immunologicals for canidae, live viral and inactivated bacterial vaccines.
Croatian: Farmakoterapijska grupa: imunološki pripravci za pse, živa virusna i inaktivirana bakterijska cjepiva.
English: However, the vaccine has been proven to be protective against virulent challenge in the presence of maternally derived antibodies to CDV, CAV and CPV at levels equal or higher to those likely to be encountered under field conditions.
Croatian: Međutim, dokazano je cjepivo štiti od virulentno izazvanog imunološkog odgovora u prisutnosti majčinskih protutijela kod CDV, CAV i CPV u jednakoj ili većoj razini od onih koje se najčešće susreću u terenskim uvjetima.
English: Suspension (inactivated): L. interrogans serovar Icterohaemorrhagiae
Croatian: Suspenzija (inaktivirana): L. interrogans serovar Icterohaemorrhagiae
English: It was shown that 3 years after the vaccination CAV-2 antibodies are still present.
Croatian: Pokazalo se da su 3 godine nakon cijepljenja protiv CAV-2, protutijela još uvijek prisutna.
English: The vaccine virus strain CPV-2b has not been tested in other carnivores (except dogs and domestic cats) that are known to be susceptible to canine parvoviruses and therefore vaccinated dogs should be separated from them after vaccination.
Croatian: Cjepni soj CPV-2b nije testiran na drugim mesožderima (osim pasa i domaćih mačaka) koji su osjetljivi na pseće parvoviruse i zbog toga je potrebno nakon cijepljenja odvojeno držati cijepljene pse.
English: In case of need, dogs younger than 8 weeks can be vaccinated as safety of Versican Plus DHPPi/L4R has been demonstrated in 6 weeks old dogs.
Croatian: U slučaju potrebe mogu se cijepiti psi mlađi od 8 tjedana, jer je dokazana neškodljivost Versican Plus DHPPi/L4R kod pasa starih 6 tjedana.
English: The duration of immunity against CAV-2 was not established by challenge.
Croatian: Trajanje imuniteta protiv CAV-2 nije utvrđeno izazivanjem imunološkog odgovora.
English: MARKETING AUTHORISATION NUMBER(S) EU/2/14/164/001
Croatian: BROJ(EVI) ODOBRENJA ZA STAVLJANJE U PROMET EU/2/14/164/001
English: Suspension: whitish colour with fine sediment.
Croatian: Suspenzija: bjelkaste boje s finim talogom.
English: Sodium chloride
Croatian: Natrijev klorid Kalijev klorid
English: Immunological responses to the CDV, CAV and CPV components of the vaccine may be delayed due to maternally derived antibody interference.
Croatian: Imunološki odgovor na komponente cjepiva CDV, CAV i CPV može biti odgođen zbog interferencije s majčinskim protutijelima (MDA).
English: Annual re-vaccination is required for Parainfluenza and Leptospira components, therefore a single dose of compatible vaccine Versican Plus Pi/L4 can be used annually as required.
Croatian: Godišnje docjepljivanje potrebno je za Parainfluenca i Leptospira komponente, stoga se pojedinačna doza kompatibilnog cjepiva Versican Plus Pi/L4 može primjenjivati godišnje prema potrebi.
English: The vaccine is intended for the active immunisation of healthy puppies and dogs against diseases caused by canine distemper virus, canine parvovirus, canine adenovirus type 1 and 2, canine parainfluenza virus, Leptospira interrogans serogroup Australis serovar Bratislava, Leptospira interrogans serogroup Canicola serovar Canicola, Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa and Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae.
Croatian: Cjepivo je namijenjeno aktivnoj imunizaciji zdrave štenadi i zdravih pasa protiv bolesti koje uzrokuje virus štenećaka, pseći parvovirus, pseći adenovirus tip 1 i tip 2, pseći virus parainfluence, Leptospira interrogans serotip Australis serovar Bratislava, Leptospira interrogans serotip Canicola serovar Canicola, Leptospira kirschneri serotip Grippotyphosa serovar Grippotyphosa i Leptospira interrogans serotip Icterohaemorrhagiae serovar Icterohaemorrhagiae.
English: The live attenuated virus vaccine strains CAV-2, CPiV and CPV-2b may be shed by vaccinated dogs following vaccination, shedding of CPV has been shown for up to 10 days.
Croatian: Žive atenuirane cjepne sojeve CAV-2, CPiV i CPV-2b psi mogu nakon cijepljenja izlučivati u okoliš, izlučivanje u okoliš soja CPV je primijećeno do najviše 10 dana.
English: Second dose: Versican Plus DHPPi/L4R 3-4 weeks later but not before 12 weeks of age.
Croatian: Druga doza: Versican Plus DHPPi/L4R 3-4 tjedna kasnije, ali ne prije navršenih 12 tjedana života.
English: VIALS (1 DOSE LYOPHILISATE)
Croatian: BOČICA (1 DOZA LIOFILIZATA)
English: Reconstituted vaccine: pinkish or yellowish colour with slight opalescence.
Croatian: Rekonstituirano cjepivo: ružičasta ili žućkasta boja s blagom opalescencijom.
English: In case of travelling to risk areas or outside the EU, veterinary surgeons may wish to give additional rabies vaccinations after 12 weeks of age to ensure that the vaccinated dogs have an antibody titre of ≥ 0.5 IU/ml, which is generally regarded as sufficiently protective and that they meet the travel test requirements (antibody titres ≥ 0.5 IU/ml).
Croatian: U slučajevima putovanja u rizična područja ili izvan EU-a, veterinari će mogu zatražiti da se provedu dodatna cijepljenja protiv bjesnoće nakon navršenih 12 tjedana starosti kako bi se osiguralo da cijepljeni psi imaju titar antitijela od ≥ 0,5 IU/ml, koji se u pravilu smatra dovoljnom zaštitom, te da psi ispunjavaju zahtjeve testa za putovanja (titar antitijela ≥ 0,5 IU/ml).
English: A single dose of Versican Plus DHPPi/L4 should be given every 3 years.
Croatian: Jedna doza Versican Plus DHPPi/L4 svake tri godine.
English: In case of travelling to risk areas or outside the EU, veterinary surgeons may wish to give additional rabies vaccinations after 12 weeks of age to ensure that the vaccinated dogs have an antibody titre of ≥ 0.5 IU/ml, which is generally regarded as sufficiently protective and that they meet the travel test requirements ( antibody titres ≥ 0.5 IU/ml).
Croatian: U slučajevima putovanja u rizična područja ili izvan EU-a, veterinari mogu zatražiti da se provedu dodatna cijepljenja protiv bjesnoće nakon navršenih 12 tjedana starosti kako bi se osiguralo da cijepljeni psi imaju titar antitijela od ≥ 0,5 IU/ml, koji se u pravilu smatra dovoljnom zaštitom te da psi ispunjavaju zahtjeve testa za putovanja (titar antitijela ≥ 0,5 IU/ml).
English: Canine adenovirus Type 2, strain CAV-2 Bio 13
Croatian: Pseći adenovirus tip 2, soj CAV-2-Bio 13
English: At least one year following the primary vaccination course for canine parainfluenza virus and Leptospira components.
Croatian: Najmanje godinu dana nakon osnovnog cijepljenja za komponente CPiV i Leptospira.
English: First dose: Versican Plus DHPPi/L4 from 8-9 weeks of age.
Croatian: Prva doza: Versican Plus DHPPi/L4 nakon navršenih 8-9 tjedna starosti.
English: Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa, strain MSLB 1091
Croatian: Leptospira kirschneri serotip Grippotyphosa serovar Grippotyphosa, soj MSLB 1091
English: − 3 weeks after the first vaccination for CDV, CAV, CPV,
Croatian: Najmanje tri godine nakon osnovnog cijepljenja za CDV, CAV-1, CAV-2 i CPV.
English: MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
Croatian: PROIZVOĐAČI BIOLOŠKI DJELATNE TVARI I PROIZVOĐAČI ODGOVORAN ZA PUŠTANJE SERIJE U PROMET
English: Type I glass vial containing 1 ml of suspension closed with a chlorobutyl rubber stopper and aluminium cap.
Croatian: I sadržavaju 1 ml suspenzije zatvorene brombutilnim gumenim čepom i aluminijskom kapicom.
English: Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae strain MSLB 1089
Croatian: Leptospira interrogans serotip Icterohaemorrhagiae serovar Icterohaemorrhagiae, soj MSLB 1089
English: Leptospira interrogans serogroup Australis serovar Bratislava, strain MSLB 1088
Croatian: Leptospira interrogans serotip Australis serovar Bratislava, soj MSLB 1088
English: Potassium chloride Potassium dihydrogen phosphate Disodium phosphate dodecahydrate Water for injection
Croatian: Kalijev dihidrogen fosfat Dinatrijev fosfat dodekahidrat.
English: Type I glass vial containing 1 dose of lyophilisate closed with a bromobutyl rubber stopper and aluminium cap.
Croatian: I sadržavaju 1 dozu liofilizata zatvorene brombutilnim gumenim čepom i aluminijskom kapicom.
English: If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.
Croatian: Ako zamijetite bilo koju nuspojavu ili druge nuspojave koje nisu opisane u uputi o VMP ili mislite da
English: STATEMENT OF ACTIVE SUBSTANCES Each dose of 1 ml contains:
Croatian: Svaka doza od 1 ml sadržava: Djelatne tvari:
English: Leptospira interrogans serogroup Canicola serovar Canicola, strain MSLB 1090
Croatian: Leptospira interrogans serotip Canicola serovar Canicola, soj MSLB 1090
English: Active substances:
Croatian: SASTAV DJELATNIH TVARI
English: 1.8-2.2 mg. For the full list of excipients, see section 6.1.
Croatian: Potpuni popis pomoćnih tvari vidi u odjeljku 6.1.
English: No other adverse reactions other than those mentioned in section 4.6 were observed after administration of a 10-fold overdose of the vaccine.
Croatian: Nakon primjene deseterostruke propisane doze nisu zapažene druge nuspojave osim onih navedenih u odjeljku 4.6. Međutim, kod manjeg broja pasa uočena je bolnost na mjestu aplikacije odmah po primjeni deseterostruke doze.
English: 103.6 TCID50* 105.3 TCID50 Canine parvovirus Type 2b, strain CPV-2b Bio 12/B 10
Croatian: Pseći parvovirus tip 2b, soj CPV-2b-Bio 12/B
English: PACKAGE LEAFLET: Versican Plus DHPPi/L4 lyophilisate and suspension for suspension for injection for dogs
Croatian: Versican Plus DHPPi/L4 liofilizat i suspenzija za suspenziju za injekciju za pse
English: No other adverse effects other than those mentioned under section 6 (Adverse reactions) have been observed after administration of a 10-fold overdose of the vaccine.
Croatian: Nakon primjene deseterostruke propisane doze nisu zapažene druge nuspojave osim onih navedenih u odjeljku 6 (Nuspojave).
English: Primary vaccination scheme: Two doses of Versican Plus DHPPi/L4 3-4 weeks apart from 6 weeks of age.
Croatian: Dvije doze Versican Plus DHPPi/L4 u razmaku od 3-4 tjedna nakon navršenih 6 tjedana starosti.
English: TCID50
Croatian: Trometamol
English: − to prevent mortality and clinical signs caused by canine adenovirus type 1,
Croatian: - sprječavanje uginuća i kliničkih znakova bolesti uzrokovanih virusom štenećaka, - sprječavanje uginuća i kliničkih znakova bolesti uzrokovanih psećim adenovirusom tipa 1, - sprječavanje kliničkih znakova i smanjivanje izlučivanja virusa uzrokovanog psećim adenovirusom tipa 2,
English: CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Veterinary medicinal product subject to prescription.
Croatian: UVJETI ILI OGRANIČENJA U POGLEDU OPSKRBE I PRIMJENE C. IZVJEŠĆE O MRL
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Versican Plus DHPPi/L4 suspension for dogs
Croatian: Versican Plus DHPPi/L4 suspenzija za pse
English: Canine distemper virus
Croatian: Virus štenećaka
English: − to prevent clinical signs and urinary excretion and reduce infection caused by L. interrogans serogroup Canicola serovar Canicola and L. interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae, and
Croatian: - sprječavanje kliničkih znakova, leukopenije i izlučivanja virusa uzrokovanog psećim parvovirusom, - sprječavanje kliničkih znakova (iscjedak iz nosa i očiju) i smanjivanje izlučivanja virusa uzrokovanog virusom parainfluence, - sprječavanje kliničkih znakova, infekcije i urinarne ekskrecije uzrokovane L. interrogans serotip Australis, serovar Bratislava, - sprječavanje kliničkih znakova i urinarne ekskrecije i smanjivanje infekcije uzrokovane L. interrogans serotip Canicola serovar Canicola i L. interrogans serotip Icterohaemorrhagiae serovar Icterohaemorrhagiae, - sprječavanje kliničkih znakova i smanjivanje infekcije i urinarne ekskrecije uzrokovane L. kirschneri serotip Grippotyphosa serovar Grippotyphosa.
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Versican Plus DHPPi/L4 lyophilisate for dogs
Croatian: Versican Plus DHPPi/L4 liofilizat za pse
English: − to prevent clinical signs, leucopoenia and viral excretion caused by canine parvovirus,
Croatian: - sprječavanje kliničkih znakova i urinarne ekskrecije i smanjivanje infekcije uzrokovane L.
English: Pregnancy lactation:
Croatian: Osnovno cijepljenje (primovakcinacija):
English: − to prevent clinical signs (nasal and ocular discharge) and reduce viral excretion caused by canine parainfluenza virus,
Croatian: - sprječavanje kliničkih znakova, leukopenije i izlučivanja virusa uzrokovanog psećim parvovirusom, - sprječavanje kliničkih znakova (iscjedak iz nosa i očiju) i smanjivanje izlučivanja virusa uzrokovanog virusom parainfluence, - sprječavanje kliničkih znakova, infekcije i urinarne ekskrecije uzrokovane L. interrogans serotip
English: Canine parainfluenza Type 2 virus, strain CPiV-2 Bio 15 103.1 TCID50* 105.1 TCID50 Suspension (inactivated):
Croatian: Pseći parainfluenca virus tip 2, soj CPiV-2-Bio 15